WO2014153643A8 - Compositions and methods for use thereof in the treatment of aniridia - Google Patents
Compositions and methods for use thereof in the treatment of aniridia Download PDFInfo
- Publication number
- WO2014153643A8 WO2014153643A8 PCT/CA2014/000286 CA2014000286W WO2014153643A8 WO 2014153643 A8 WO2014153643 A8 WO 2014153643A8 CA 2014000286 W CA2014000286 W CA 2014000286W WO 2014153643 A8 WO2014153643 A8 WO 2014153643A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- treatment
- methods
- nonsense mutation
- aniridia
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Provided herein are methods for treating a nonsense mutation eye condition, the method comprising the topical administration of one or more nonsense mutation read-through agent(s) formulated for topical delivery to the eye of a subject in need thereof and topical formulations of one or more nonsense mutation read-through agent(s) for use in the treatment of a nonsense mutation eye condition.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361805253P | 2013-03-26 | 2013-03-26 | |
US61/805,253 | 2013-03-26 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2014153643A1 WO2014153643A1 (en) | 2014-10-02 |
WO2014153643A8 true WO2014153643A8 (en) | 2014-11-06 |
Family
ID=51622304
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA2014/000286 WO2014153643A1 (en) | 2013-03-26 | 2014-03-26 | Compositions and methods for use thereof in the treatment of aniridia |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2014153643A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI695717B (en) * | 2014-03-06 | 2020-06-11 | 美商 Ptc 治療公司 | Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid |
TN2017000097A1 (en) | 2014-10-24 | 2018-07-04 | Takeda Pharmaceuticals Co | Heterocyclic compound |
US20240024292A1 (en) * | 2020-12-14 | 2024-01-25 | Institut National de la Santé et de la Recherche Médicale | Ataluren eye drop formulation |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8716321B2 (en) * | 2005-04-08 | 2014-05-06 | Ptc Therapeutics, Inc. | Methods for dosing an orally active 1,2,4-oxadiazole |
CL2007002743A1 (en) * | 2006-09-25 | 2008-07-11 | Pct Therapeutics Inc Soc Organ | CRYSTALLINE FORM OF ACID 3- [5- (2-FLUOROPHENYL) - [1,2,4] OXADIAZOL-3-IL] -BENZOIC; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH CRYSTAL FORM; AND ITS USE TO MODULATE MARN'S PREMATURE TRANSFER OR DECLINE TERMINATION, SUCH AS CARCICOMA. |
-
2014
- 2014-03-26 WO PCT/CA2014/000286 patent/WO2014153643A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2014153643A1 (en) | 2014-10-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL267997A (en) | Compositions, formulations and methods for treating ocular diseases | |
MX2017007321A (en) | Combination therapies. | |
EP3166648A4 (en) | Compositions and delivery methods for treating dental infections, inflammation, sensitivity, and for use in dental restorations | |
MX2015009105A (en) | Solid solution compositions and use in chronic inflammation. | |
EP3156081A4 (en) | Cell structure for use in treatment of brain injury, method for producing same, and therapeutic agent for brain injury | |
MX2015009058A (en) | Compositions and methods for treating chronic inflammation and inflammatory diseases. | |
WO2015044782A3 (en) | Intranasal dhe for the treatment of headache | |
WO2014143855A3 (en) | Combination cancer treatments utilizing micrornas and egfr-tki inhibitors | |
MX2015010791A (en) | Methods of treating cancer and preventing drug resistance. | |
IN2013MU03583A (en) | ||
IL251836A0 (en) | Compositions and methods for physiological delivery using cannabidiol | |
MX2015009045A (en) | Compositions and methods for treating severe pain. | |
EP3332012A4 (en) | Glp-1 and use thereof in compositions for treating metabolic diseases | |
NZ744323A (en) | Compositions comprising 15-hepe and methods of using the same | |
MA40460A (en) | Lysosomal targeting and uses thereof | |
PH12016500863A1 (en) | Tetracyclic autotaxin inhibitors | |
EP3337482A4 (en) | Transdermal formulations for delivery of berberine compounds, and their use in the treatment of berberine-responsive diseases and conditions | |
PH12016501371A1 (en) | Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same | |
GB201302343D0 (en) | Pharmaceutical compositions comprising 15-OHEPA and methods for using the same | |
EP3359553A4 (en) | Compositions and methods for treating diabetic retinopathy | |
WO2014153643A8 (en) | Compositions and methods for use thereof in the treatment of aniridia | |
PH12016501434A1 (en) | Compositions for use in the treatment of allergic conditions | |
WO2013170086A3 (en) | Formulations for the delivery of active ingredients | |
MX2015013151A (en) | Methods of treating dyskinesia and related disorders. | |
EP3344233A4 (en) | Transdermal formulations for delivery of doxycycline, and their use in the treatment of doxycycline-responsive diseases and conditions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14775981 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 14775981 Country of ref document: EP Kind code of ref document: A1 |